DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Hermansky-Pudlak syndrome 3 — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleHermansky-Pudlak syndrome 3 maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for hermansky-pudlak syndrome 3 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
ceruloplasmin (CP) — CP is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet oxydrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 4ENZ · 2.6 Å · ligand OXYGEN MOLECULE (OXY). Experimental structure, not a prediction.
What the evidence adds up to
Hermansky-Pudlak syndrome 3 is a rare autosomal-recessive disorder. The abstracts describe HPS generally, not type 3 specifically. Clinically, the syndrome is characterised by oculocutaneous albinism, platelet storage pool deficiency that causes prolonged bleeding, and ceroid lipofuscin deposition. Major organ involvement includes pulmonary fibrosis and granulomatous colitis; cardiomyopathy and renal dysfunction have been described rarely. Affected individuals may suffer from blindness, colitis, and bleeding diathesis. The syndrome was first described in 1959.
The highest frequency occurs in a cluster population in the northwest corner of Puerto Rico, where the carrier incidence is 1 in 21. Although HPS has been reported in various ethnic groups globally, no prevalence figures for type 3 outside Puerto Rico are given. One abstract reports a case of the oldest historical patient with HPS type 6 and its gastrointestinal management, but no such case is described for type 3. The majority of HPS genes have been described as novel, but a conserved protein family including human HPS4 has been identified, and distant homologs for other HPS genes exist, suggesting the cellular machinery involved is ancient.
No clinical trial data, survival statistics, response rates, or treatment outcomes for HPS-3 are provided in these abstracts. There is no mention of any drug therapy, repurposed or otherwise, for any HPS subtype. What is still missing is any prospective study of HPS-3 natural history, a validated patient registry, stratified outcome measures for pulmonary fibrosis and colitis, and funding for a controlled trial of any candidate intervention.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Journal of Clinical Gastroenterology · 2010 · 37 citations
The Management of Gastrointestinal Disease in Hermansky-Pudlak Syndrome
AbstractHermansky-Pudlak syndrome (HPS) was first described in 1959 by Hermansky and Pudlak. Clinically, HPS is characterized by oculocutaneous albinism, platelet storage pool deficiency, and ceroid tissue accumulation. It is a rare disorder that has been described globally but has the highest frequency in a cluster population in Puerto Rico. HPS patients also have major organ involvement that typically includes pulmonary fibrosis and granulomatous colitis. Rarely have cardiomyopathy and renal dysfunction been described. We report a case of the oldest historical patient with HPS type 6 and the associated gastrointestinal management.
The CHiPS Domain – Ancient Traces for the Hermansky–Pudlak Syndrome
AbstractHermansky-Pudlak syndrome (HPS) is a rare disorder caused by malfunctions of lysosomes and specialized lysosome-related organelles, resulting primarily in oculocutaneous albinism and bleeding diathesis. The majority of the HPS genes have been described as novel, but herein we report the identification of a conserved protein family which includes human HPS4, as well as distant homologs for other HPS genes. Our results suggest that the cellular machinery involved in the HPS syndrome is ancient.
American Journal of Perinatology · 2009 · 5 citations
Hermansky-Pudlak Syndrome in Pregnancy
AbstractHermansky-Pudlak syndrome (HPS) is a multisystem, autosomal-recessive disorder characterized by oculocutaneous albinism, platelet storage pool deficiency resulting in prolonged bleeding, and ceroid lipofuscin deposition. Affected individuals may suffer from blindness, pulmonary fibrosis, colitis, and bleeding diathesis. Although it has been reported in various ethnic groups, HPS is most common in individuals from the northwest corner of Puerto Rico, with a carrier incidence of 1 in 21.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
